Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

Table 4

The assessment results based on Target Plaque Severity Score at each assessment timepoint during treatment.

		Dose group
		0.50%	1.00%	2.00%	4.00%	Vehicle	Total	P value
		(N=8)	(N=9)	(N=8)	(N=8)	(N=7)	(N=40)
	Cured	0	0	0	0	0	0	p=0.016
	Obviously effective	0	0	0	0	0	0
Day 8	Effective	0	2 (22.2%)	4 (50.0%)	7 (87.5%)	3 (42.9%)	16 (40.0%)
	No effect	8 (100.0%)	7 (77.8%)	4 (50.0%)	1 (12.5%)	2 (28.6%)	22 (55.0%)
	Deteriorating	0	0	0	0	2 (28.6%)	2 (5.0%)
	Total	8 (100.0%)	9 (100.0%)	8 (100.0%)	8 (100.0%)	7 (100.0%)	40 (100.0%)
	Cured	0	0	0	0	0	0	p=0.138
	Obviously effective	0	0	0	0	1 (14.3%)	1 (2.5%)
Day 15	Effective	1 (12.5%)	3 (33.3%)	4 (50.0%)	7 (87.5%)	3 (42.9%)	18 (45.0%)
	No effect	7 (87.5%)	5 (55.6%)	3 (37.5%)	1 (12.5%)	1 (14.3%)	17 (42.5%)
	Deteriorating	0	1 (11.1%)	1 (12.5%)	0	2 (28.6%)	4 (10.0%)
	Total	8 (100.0%)	9 (100.0%)	8 (100.0%)	8 (100.0%)	7 (100.0%)	40 (100.0%)
	Cured	0	0	0	0	0	0	p=0.196
	Obviously effective	0	0	0	1 (12.5%)	0	1 (2.6%)
Day 22	Effective	3 (37.5%)	5 (62.5%)	7 (87.5%)	6 (75.0%)	4 (57.1%)	25 (64.1%)
	No effect	5 (62.5%)	2 (25.0%)	0	1 (12.5%)	3 (42.9%)	11 (28.2%)
	Deteriorating	0	1 (12.5%)	1 (12.5%)	0	0	2 (5.1%)
	Total	8 (100.0%)	8 (100.0%)	8 (100.0%)	8 (100.0%)	7 (100.0%)	39 (100.0%)
	Cured	0	0	0	0	0	0	p=0.475
	Obviously effective	0	0	1 (12.5%)	1 (12.5%)	0	2 (5.1%)
Day 28	Effective	4 (50.0%)	5 (62.5%)	5 (62.5%)	6 (75.0%)	5 (71.4%)	25 (64.1%)
	No effect	4 (50.0%)	3 (37.5%)	1 (12.5%)	1 (12.5%)	2 (28.6%)	11 (28.2%)
	Deteriorating	0	0	1 (12.5%)	0	0	1 (2.6%)
	Total	8 (100.0%)	8 (100.0%)	8 (100.0%)	8 (100.0%)	7 (100.0%)	39 (100.0%)